Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373704 | 0.89 | HRH3 (0.48) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL10274867 | 0.82 | HRH3 (0.55) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL4055980 | 0.82 | HRH3 (0.55) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL1295721 | 0.81 | HRH3 (0.51) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL28492122 | 0.81 | HRH3 (0.51) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL186721 | 0.81 | HRH3 (0.51) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL13291479 | 0.81 | HRH3 (0.54) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL28055168 | 0.81 | HRH3 (0.77) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL374206 | 0.81 | HRH3 (0.54) | HRH3HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL1764566 | 0.79 | HRH3 (0.60) | HRH3HPGDKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11602528-B2 | Method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives | AMICUS THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3782655-A1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-109496213-A | Spiro-compound and its preparation and application | 阿比德治疗公司 | 2019-03-19 | — | — | CN | disclosed |
| EP-3441090-A1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2932982-B1 | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives | AMICUS THERAPEUTICS INC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20180221357-A1 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-1896083-B1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | AMICUS THERAPEUTICS INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160051528-A1 | Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-02-25 | — | — | US | disclosed |
| US-9181184-B2 | Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives | AMICUS THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2932982-A1 | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives | Amicus Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| CN-101355971-A | Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives | AMICUS THERAPEUTICS INC (US) | 2009-01-28 | — | — | CN | disclosed |
| EP-1896083-A2 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060264467-A1 | Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-11-23 | — | — | US | disclosed |
| WO-2006125141-A2 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221357-A1 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | GAA, MAN2B1, MAN1B1 | HRH3 4743/4885HPGD 1997/4885KMT2A 3948/4885 |
| US-20160051528-A1 | Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives | GAA, MAN2B1, MAN1B1 | HRH3 4743/4885HPGD 1948/4885KMT2A 4027/4885 |
| US-20060264467-A1 | Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives | GAA, MAN2B1, MAN1B1 | HRH3 4738/4885HPGD 2049/4885KMT2A 4003/4885 |
| US-11602528-B2 | Method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives | GAA, MAN2B1, MAN1B1 | HRH3 4743/4885HPGD 1997/4885KMT2A 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.